KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EBIT: 2010-2025

Historic EBIT for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to -$862,000.

  • TherapeuticsMD's EBIT rose 23.99% to -$862,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year increase of 74.12%. This contributed to the annual value of -$4.8 million for FY2024, which is 44.15% up from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's EBIT is -$862,000, which was down 24.03% from -$695,000 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's EBIT registered a high of $48.4 million during Q4 2022, and its lowest value of -$39.9 million during Q3 2021.
  • Over the past 3 years, TherapeuticsMD's median EBIT value was -$1.1 million (recorded in 2024), while the average stood at -$1.4 million.
  • As far as peak fluctuations go, TherapeuticsMD's EBIT surged by 236.87% in 2022, and later tumbled by 103.33% in 2023.
  • TherapeuticsMD's EBIT (Quarterly) stood at -$35.4 million in 2021, then soared by 236.87% to $48.4 million in 2022, then crashed by 103.33% to -$1.6 million in 2023, then soared by 143.45% to $700,000 in 2024, then rose by 23.99% to -$862,000 in 2025.
  • Its last three reported values are -$862,000 in Q3 2025, -$695,000 for Q2 2025, and -$871,000 during Q1 2025.